GLPwatch

[Exenatide stimulated solute-free water excretion by human kidney].

Ross Fiziol Zh Im I M Sechenova · 2012

Last updated 2026-05-28

In a study of 55 people, including 38 with type 2 diabetes but no kidney disease, a 10 microgram dose of exenatide (a GLP-1 drug) increased urine production when combined with a water intake of 0.7% of body weight. The increase in urine output was due to higher removal of solute-free water, suggesting exenatide may play a role in the body’s water balance system.

AI summary of the abstract below.

JournalRoss Fiziol Zh Im I M Sechenova, 2012
Citations8
Relative citation ratio0.23
NIH percentile15
Molecules exenatide

Abstract

Exenatide effect was studied in 55 human including 38 patients with type 2 diabetes mellitus without signs of diabetic nephropathy and primary renal diseases. Preliminary study with water load in volume from 0.5 to 1% b.w. showed that water load equal to 0.7% b.w. caused significant increase in urine excretion. The rise of diuresis after 10 microg Byetta (exenatide) injection and simultaneous water load of 0.7% of b.w. depended on increase in solute-free water clearance. Thus, exenatide (mimetic of GLP-1) action let us to consider its possible role as component of osmoregulation system in human. This peptide provides high efficiency of renal function in osmotic homeostasis.

Verbatim abstract via PubMed 23155627 ↗

Related research